Avanafil

Major

Avanafil Abametapir Increased exposure of CYP3A4 substrate Details Avanafil Adagrasib Krazati Increased CYP3A4 substrate exposure Details Avanafil Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Avanafil Atazanavir Reyataz Decreased avanafil clearance and increased avanafil plasma concentrations Details Avanafil Avacopan Tavneos Increased CYP3A4 substrate exposure Details Avanafil Boceprevir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Carbamazepine Carbatrol Reduced avanafil exposure and reduced efficacy of avanafil Details Avanafil Clarithromycin Biaxin Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Cobicistat Tybost Increased avanafil exposure and increased risk of avanafil-related adverse events Details Avanafil Conivaptan Vaprisol Reduced avanafil clearance and increased avanafil exposure Details Avanafil Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Avanafil Darunavir Increased avanafil exposure and an increased risk of avanafil-related adverse reactions Details Avanafil Duvelisib Copiktra Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Avanafil Efavirenz Decreased avanafil plasma concentrations Details Avanafil Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avanafil Erythromycin Erythrocin Stearate Increased avanafil exposure and an increased risk of avanafil-related adverse effects Details Avanafil Etravirine Intelence Altered avanafil plasma concentrations Details Avanafil Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Avanafil Fexinidazole An increased CYP3A4 substrate exposure Details Avanafil Fluconazole Diflucan Increased avanafil exposure Details Avanafil Fosnetupitant Increased exposure of CYP3A4 substrate Details Avanafil Idelalisib Zydelig Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Indinavir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Ivosidenib Tibsovo Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details Avanafil Ketoconazole Extina Reduced avanafil clearance and increased avanafil exposure Details Avanafil Larotrectinib Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Avanafil Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Avanafil Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure Details Avanafil Lonafarnib Zokinvy Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Avanafil Lopinavir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Mifepristone Korlym Increased CYP3A4 substrate exposure Details Avanafil Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Avanafil Nefazodone Decreased avanafil clearance and increased avanafil plasma concentrations Details Avanafil Nelfinavir Viracept Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Netupitant Increased exposure of CYP3A4 substrate Details Avanafil Nevirapine Viramune Decreased avanafil plasma concentrations Details Avanafil Nirmatrelvir Increased avanafil exposure Details Avanafil Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Avanafil Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avanafil Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details